A director at Veracyte Inc sold 14,731 shares at 38.339USD and the significance rating of the trade was 74/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Two concerns we have previously highlighted on our march to new highs have been (1) improved RS from defensive Sectors/Groups and (2) weak foreign equity markets. Defensive posturing and lack of global participation has had a dampening effect on risk sentiment in recent months. While questions remain, short-term developments highlighted below are encouraging and improve our already constructive outlook. • On cue, outperformance last week and yesterday from cyclical pockets of the market led t...
Summary Veracyte Inc (Veracyte) is a molecular diagnostics company that uses genomic technology to resolve diagnostic ambiguity. The company’s pipeline products include Afirma thyroid FNA analysis for the diagnosis of thyroid cancer based on its proprietary afirma gene expression classifier. It also provides percepta bronchial genomic classifier an assay to evaluate patients with lung nodules that are suspected for cancer. Veracyte provides genomic testing to other areas of substantial clinic...
Small-caps, biotech, Discretionary hitting new highs We remain bullish on the market, but to be clear, this is not a blanket endorsement. As we outline below, the “market†has pockets of strength and pockets of weakness. Our aim as always, is to highlight each and guide our clients to areas of outperformance. With that said, let's consider the weight of the evidence for the current state of our market and our bullish recommendation. • Positives. Helping support the bull case are a number...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT) today announced that it will commercially launch its Afirma Xpression Atlas and present performance data for the RNA sequencing-based platform at the AACE 27th Annual Scientific & Clinical Congress. The Afirma Xpression Atlas leverages robust genomic content to provide physicians with gene alteration information that may help guide surgery and treatment decisions in patients with potentially cancerous thyroid nodules. Additionally, data from multiple “real wo...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson, chairman and chief executive officer, will present at the 2018 UBS Global Healthcare Conference on Wednesday, May 23, 2018 at 9:00 a.m. Eastern Time in New York, NY. The live webcast of the presentation and a subsequent replay may be accessed by visiting Veracyte's website at http://investor.veracyte.com. The replay of the webcast will be available shortly after the conclusion of the presentation and ar...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson, chairman and chief executive officer, will present at the 2018 UBS Global Healthcare Conference on Wednesday, May 23, 2018 at 11:00 a.m. Eastern Time in New York, NY. The live webcast of the presentation and a subsequent replay may be accessed by visiting Veracyte's website at http://investor.veracyte.com. The replay of the webcast will be available shortly after the conclusion of the presentation and a...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the first quarter ended March 31, 2018 and provided an update on recent business progress. For the first quarter of 2018, revenue was $20.0 million, an increase of 22%, compared to $16.4 million for the first quarter of 2017. “We had a great quarter in which we beat revenue and genomic test volume growth expectations and generated strong momentum across our business,” said Bonnie Anderson, chairman and chief exec...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT) announced today that it will report its first quarter 2018 financial results after the close of market on Tuesday, May 1, 2018. Following the announcement, Veracyte will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the company's financial results and provide a general business update. The call may be accessed as follows: Veracyte First Quarter 2018 Conference Call, May 1, 2018 at 4:30 p.m. ET ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT) today announced a research collaboration through which Loxo Oncology will access Veracyte’s new Afirma® Xpression Atlas platform to advance its development of highly selective medicines for patients with genetically defined cancers, including thyroid cancer. Through the new agreement, Veracyte will use its Afirma Xpression Atlas platform to provide Loxo Oncology with information regarding thyroid cancers with TRK fusions and RET alterations, f...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT) today announced that its soon-to-be-launched Afirma Xpression Atlas platform was unveiled at ENDO 2018, the annual meeting of the Endocrine Society, being held March 17-20 in Chicago. The RNA sequencing-based product will be offered as an extension to Veracyte’s market-leading Afirma Genomic Sequencing Classifier (GSC) and was previewed in an oral presentation and “product theater” event at the meeting. The Afirma Xpression Atlas will provide ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT) today announced that new data presented at ENDO 2018, the annual meeting of the Endocrine Society, suggest that the Afirma Genomic Sequencing Classifier (GSC) can help significantly more patients avoid unnecessary surgery in thyroid cancer diagnosis, compared to the original Afirma test. The findings were presented in a poster session during the conference, being held March 17-20 in Chicago. “Our study is the first to assess how the Afirma GSC perfor...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.